A Phase 2 interventional study of Personalised rate-response settings in Chronic Heart Failure, sponsored by University of Leeds. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-25.
Sponsored by University of Leeds · Phase 2, Interventional, and Treatment
The investigators have demonstrated that they can reliably identify an optimum heart rate range for contractility of the left ventricle in patients with chronic heart failure (CHF). They have also demonstrated in an acute cross-over study that keeping the heart rate in this range (versus standard rate-response programming) in patients with CHF is associated with increased exercise time on a treadmill (around 60s or 10%). They now want to explore in a randomised, placebo-controlled trial whether optimal programming versus standard rate-response programming for 6 months leads to appreciable improvements in exercise time and quality of life, while having no adverse effects on left ventricular function and battery longevity.
60 patients with CHF and a pacemaker will undergo the non-invasive echocardiographic assessment to establish the force frequency relationship and the optimal heart rate for contractility. They will then perform a treadmill walk test and fill out a quality of life questionnaire. They will then be randomised to optimal rate-response settings or standard rate response settings and followed up at 6 months at which point the tests will be repeated.
Design: This will be a randomised, double-blind 'placebo' controlled trial of optimised programming versus standard rate-response settings, aiming to determine whether the short term improvements translate into longer term benefits.
Study participants: 60 adult patients (>18years) aiming for 50 matched datasets (25 in each arm).
Study Procedures: Patients attending the heart failure clinic, the pacemaker clinic or previous participants in the acute cross-over study (pilot data 2) will be approached with a standard letter and information sheet and then a telephone call to make sure any remaining questions are answered.
Patients agreeing to participate will attend the clinical research facility (CRF) and will be asked to sign a consent form. Each patient will have a standard device check, check of their demographic data, and co-morbidities. The investigators will record a resting cardiac ultrasound, and, in those who did not participate in the pilot study (or did so more than six months previously), we will measure the force frequency relationship (FFR) as described to determine critical heart rate (HR), and the optimal range of HR rise. All images will be stored for offline analysis. Participants will then be asked to do a symptom-limited walk test on the treadmill (until they cannot do any more). At this first visit, participants will also complete a quality of life questionnaire. All of these activities will take place in the Clinical Research Facility at Leeds General Infirmary.
Randomisation: Each patient will then be randomised to either optimised programming (n=30) as predicted by their force-frequency curve or standard settings (n=30). In the optimised group, programming will keep heart rates below the critical HR. Randomisation will be by a random number generator and programming will be undertaken by one of my colleagues to maintain blinding.
Follow-up: Each patient will be called at one month to check that they are tolerating any changes and will then be invited back at 6 months for a repeat resting echocardiogram, treadmill walk test and quality of life assessment.
Data: All data will be stored on a bespoke Excel spreadsheet on an LTHT server in a password-protected folder.
Primary Endpoint: The effects of heart rate programming that optimises heart rate for contractility on change in treadmill-based walk distance over six months in patients with heart failure and a pacemaker.
Secondary endpoints: 1) the safety of pacemaker programming optimised for heart rate in patients with heart failure and a pacemaker, 2) the effect of this programming on change of quality of life at 6 months 3) the effect of this programming on change in cardiac function at 6 months.
5,697 studies on the registry are indexed under Heart Failure; 1,219 are open to participants now.
This study's enrollment of 83 is above the median of 72 across 3,733 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →University of Leeds is the lead sponsor of 200 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients allocated to standard rate-response settings.
Patients allocated to optimised rate-response settings.
Device: Personalised rate-response settings
Rate response range fixed to limits suggested by force-frequency curve
Treadmill walk time
Time walked during a standard incremental treadmill test
Time frame: 6 months
Quality of life
EQ5D-5L
Time frame: 6 months
Left ventricular function by echocardiography
Time frame: 6 months
Battery longevity
Measured in years remaining at current settings
Time frame: 6 months
Plan to share: Undecided
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Leeds